Inovio Pharmaceuticals (INO) Liabilities and Shareholders Equity (2010 - 2026)

Inovio Pharmaceuticals has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $49.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 42.96% year-over-year to $49.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $261.7 million (down 40.7% YoY) and the FY2025 annual result came in at $74.3 million, down 34.35% from the prior year.
• Liabilities and Shareholders Equity slipped to $49.8 million in Q1 2026 per INO's latest filing, from $74.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $459.4 million in Q2 2022 and troughed at $49.8 million in Q1 2026.
• A 5-year average of $196.5 million and a median of $133.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity retreated 22.38% in 2022, then slumped 51.57% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $348.5 million in 2022, then slumped by 50.95% to $171.0 million in 2023, then tumbled by 33.78% to $113.2 million in 2024, then tumbled by 34.35% to $74.3 million in 2025, then plunged by 33.01% to $49.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $49.8 million, $74.3 million, and $69.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.